WHAT IS CLAIMED IS:

1. A method for treating a disorder selected from: depression, perimenopausal depression, post-partum depression, premenstrual syndrome, manic depression, anxiety, dementia, obsessive compulsive behavior, mild cognitive impairment, attention deficit disorder, a sleep disorder, irritability, impulsivity, anger management, multiple sclerosis and Parkinson's disease, in a mammal by increasing the transcription of TPH which comprises administering to the mammal a therapeutically effective amount of an ERβ selective agonist.

2. The method of Claim 1 wherein the disorder is depression..

3. The method of Claim 1 wherein the disorder is anxiety.

4. The method of Claim 1 wherein the disorder is dementia.

5. The method of Claim 1 wherein the disorder is multiple sclerosis.

6. The method of Claim 1 wherein the disorder is Parkinson's disease.

7. The method of Claim 1 wherein the ERβ selective agonist is an orally active ERβ selective agonist.

8. The method of Claim 7 wherein the ERβ selective agonist is a CNS-penetrating estrogen receptor beta selective agonist.

9. A pharmaceutical composition comprising an estrogen receptor beta selective agonist and at least one other active ingredient selected from the group consisting of: norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), melatonin agonists, serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, α-adrenoreceptor antagonists and atypical anti-depressants.

10. The pharmaceutical composition of Claim 9 wherein the norepinephrine reuptake inhibitor is selected from the group consisting of amitriptyline, clomipramine, doxepin, imipramine and trimipramine, amoxapine, desipramine, maprotiline, nortriptyline and protriptyline, and pharmaceutically acceptable salts and mixtures thereof.

11. The pharmaceutical composition of Claim 9 wherein the selective serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, fluvoxamine, paroxetine and sertraline, and pharmaceutically acceptable salts and mixtures thereof.

12. The pharmaceutical composition of Claim 9 wherein the monoamine oxidase inhibitor is selected from the group consisting of isocarboxazid, phenelzine, tranylcypromine, selegiline, and the pharmaceutically acceptable salts and mixtures thereof.

13. The pharmaceutical composition of Claim 9 wherein the reversible inhibitor of monoamine oxidase is selected from the group consisting of moclobemide and the pharmaceutically acceptable salts thereof.

14. The pharmaceutical composition of Claim 9 wherein the serotonin and noradrenaline reuptake inhibitor is selected from the group consisting of venlafaxine and pharmaceutically acceptable salts thereof.

15. The pharmaceutical composition of Claim 9 wherein the atypical anti-depressant is selected from the group consisting of bupropion, lithium, nefazodone, trazodone, viloxazine, and the pharmaceutically acceptable salts and mixtures thereof.

16. The method of Claim 1 which also comprises one or more agents selected from a bisphosphonate, an estrogen, a selective estrogen receptor modulator, an androgen receptor modulator, an integrin antagonist, a cathepsin K inhibitor, an inhibitor of osteoclast proton ATPase, parathyroid hormone, calcitonin, Vitamin D, a synthetic Vitamin D analogue, and the pharmaceutically acceptable salts and mixtures thereof.